Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check36 days agoChange DetectedThe webpage has been updated to include the study's collaborators, Merck Sharp & Dohme LLC, and the study chair, Harpreet Wasan, MBBS, FRCP, from Imperial College London. Additionally, the revision number has been updated from v2.14.3 to v2.15.0.SummaryDifference53%
- Check51 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check101 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check108 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.